IBMX | CAS#28822-58-4 | nonselective phosphodiesterase inhibitor

MedKoo Cat#: 561233 | Name: IBMX

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IBMX is a competitive nonselective phosphodiesterase inhibitor. IBMX raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity. IBMX is also a nonselective adenosine receptor antagonist.

Chemical Structure

IBMX

CAS#28822-58-4

Theoretical Analysis

MedKoo Cat#: 561233

Name: IBMX

CAS#: 28822-58-4

Chemical Formula: C10H14N4O2

Exact Mass: 222.1117

Molecular Weight: 222.25

Elemental Analysis: C, 54.04; H, 6.35; N, 25.21; O, 14.40

Price and Availability

Size	Price	Availability	Quantity
250mg	USD 350.00	2 Weeks
1g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

IBMX; isobutylmethylxanthine; Methylisobutylxanthine;

IUPAC/Chemical Name

3-Isobutyl-1-methylxanthine

InChi Key

APIXJSLKIYYUKG-UHFFFAOYSA-N

InChi Code

InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)

SMILES Code

O=C(N1C)N(CC(C)C)C2=C(NC=N2)C1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC50s of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and PDE5, respectively.

In vitro activity:

Subsequently, B16/F10 melanoma cells were treated with IBMX to analyze the effect of ESB on melanin production. As shown in Figure 4B, the level of melanin content increased to 316.85% when treated with IBMX. On the other hand, the ESB treated group (108.60%) at 10 μg/mL concentration showed significantly decreased melanin contents compared to the IBMX treated group, and similar melanin contents compared to the arbutin group (101.79%) as a positive control. Reference: Nutrients. 2020 Mar 20;12(3):832. https://pubmed.ncbi.nlm.nih.gov/32245029/

In vivo activity:

There was a subsequent decrease in PDCD4 protein (0.75 ± 0.05 relative band intensity) in oocytes under IBMX inhibition at 24 h compared to control (1.2 ± 0.04 relative band intensity; P = 0.03; Fig. 2b). This suggests that IBMX inhibition of GVBD increased the abundance of MIR21 in the oocyte hastening the MIR21-driven decrease in PDCD4 abundance. Reference: Reprod Biol Endocrinol. 2020 May 11;18(1):39. https://pubmed.ncbi.nlm.nih.gov/32393269/

	Solvent	mg/mL	mM
Solubility
	DMF	5.0	22.50
	DMSO	25.6	114.99
	Ethanol	6.1	27.31

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 222.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Han HJ, Park SK, Kang JY, Kim JM, Yoo SK, Heo HJ. Anti-Melanogenic Effect of Ethanolic Extract of Sorghum bicolor on IBMX-Induced Melanogenesis in B16/F10 Melanoma Cells. Nutrients. 2020 Mar 20;12(3):832. doi: 10.3390/nu12030832. PMID: 32245029; PMCID: PMC7146600. 2. Wei Y, Liao Y, Zavilowitz B, Ren J, Liu W, Chan P, Rohatgi R, Estilo G, Jackson EK, Wang WH, Satlin LM. Angiotensin II type 2 receptor regulates ROMK-like K⁺ channel activity in the renal cortical collecting duct during high dietary K⁺ adaptation. Am J Physiol Renal Physiol. 2014 Oct 1;307(7):F833-43. doi: 10.1152/ajprenal.00141.2014. Epub 2014 Aug 6. PMID: 25100281; PMCID: PMC4187043. 3. Hale BJ, Li Y, Adur MK, Ross JW. Inhibition of germinal vesicle breakdown using IBMX increases microRNA-21 in the porcine oocyte. Reprod Biol Endocrinol. 2020 May 11;18(1):39. doi: 10.1186/s12958-020-00603-1. PMID: 32393269; PMCID: PMC7212575. 4. Candia OA, Kong CW, Alvarez LJ. IBMX-elicited inhibition of water permeability in the isolated rabbit conjunctival epithelium. Exp Eye Res. 2008 Mar;86(3):480-91. doi: 10.1016/j.exer.2007.11.021. Epub 2007 Dec 23. PMID: 18234193; PMCID: PMC2288740.

In vitro protocol:

In vivo protocol:

1. Hale BJ, Li Y, Adur MK, Ross JW. Inhibition of germinal vesicle breakdown using IBMX increases microRNA-21 in the porcine oocyte. Reprod Biol Endocrinol. 2020 May 11;18(1):39. doi: 10.1186/s12958-020-00603-1. PMID: 32393269; PMCID: PMC7212575. 2. Candia OA, Kong CW, Alvarez LJ. IBMX-elicited inhibition of water permeability in the isolated rabbit conjunctival epithelium. Exp Eye Res. 2008 Mar;86(3):480-91. doi: 10.1016/j.exer.2007.11.021. Epub 2007 Dec 23. PMID: 18234193; PMCID: PMC2288740.

1: Yoshimura K, Tada H, Anzai C. [Cystic fibrosis]. Ryoikibetsu Shokogun Shirizu. 1998;(19 Pt 2):606-11. Review. Japanese. PubMed PMID: 9645146. 2: Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002 Jul-Aug;56(6):453-9. Review. PubMed PMID: 12166544. 3: Manganiello VC, Smith CJ, Newman AH, Rice K, Degerman E, Belfrage P. Hormonal regulation of adipocyte particulate "low Km" cAMP phosphodiesterase. J Cyclic Nucleotide Protein Phosphor Res. 1986-1987;11(7):497-511. Review. PubMed PMID: 2450112. 4: Ashcroft SJ, Sugden MC, Williams IH. Carbohydrate metabolism and the glucoreceptor mechanism. Horm Metab Res Suppl. 1980;Suppl 10:1-7. Review. PubMed PMID: 6161068. 5: Bruns RF, Katims JJ, Annau Z, Snyder SH, Daly JW. Adenosine receptor interactions and anxiolytics. Neuropharmacology. 1983 Dec;22(12B):1523-9. Review. PubMed PMID: 6199685. 6: Howell SL, Tyhurst M. Insulin secretion: the effector system. Experientia. 1984 Oct 15;40(10):1098-105. Review. PubMed PMID: 6208051. 7: O'Shea Alvarez MS. 3T3 cells in adipocytic conversion. Arch Invest Med (Mex). 1991 Apr-Jun;22(2):235-44. Review. PubMed PMID: 1726451. 8: Muravyov A, Tikhomirova I. Role Ca(2+) in mechanisms of the red blood cells microrheological changes. Adv Exp Med Biol. 2012;740:1017-38. doi: 10.1007/978-94-007-2888-2_47. Review. PubMed PMID: 22453982. 9: Fredholm BB. Gastrointestinal and metabolic effects of methylxanthines. Prog Clin Biol Res. 1984;158:331-54. Review. PubMed PMID: 6084844. 10: Weir GC, Leahy JL, Bonner-Weir S. Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev. 1986;2(1-2):125-61. Review. PubMed PMID: 2424696. 11: Zufall F. Cyclic AMP-gated cation channels of olfactory receptor neurons. EXS. 1993;66:135-45. Review. PubMed PMID: 7505646. 12: Rosen OM, Smith CJ, Hirsch A, Lai E, Rubin CS. Recent studies of the 3T3-L1 adipocyte-like cell line. Recent Prog Horm Res. 1979;35:477-99. Review. PubMed PMID: 92801. 13: Niemeyer G. Retinal pharmacology in the perfused cat eye. Doc Ophthalmol. 1988 Mar-Apr;68(3-4):327-35. Review. PubMed PMID: 2456907. 14: Gilbard JP. The tear film: pharmacological approaches and effects. Adv Exp Med Biol. 1994;350:377-84. Review. PubMed PMID: 7518184. 15: Arimura A, Culler MD, Matsumoto K, Kanda M, Itoh Z, Murphy W, Shively JE, Palkovits M. Growth hormone releasing factors in the brain and the gut: chemistry, actions, and localization. Peptides. 1984;5 Suppl 1:41-4. Review. PubMed PMID: 6207512. 16: Hill HZ, Li W, Xin P, Mitchell DL. Melanin: a two edged sword? Pigment Cell Res. 1997 Jun;10(3):158-61. Review. PubMed PMID: 9266603. 17: Pekala PH, Moss J. 3T3-L1 preadipocyte differentiation and poly(ADP-ribose) synthetase. Mol Cell Biochem. 1983;53-54(1-2):221-32. Review. PubMed PMID: 6194420. 18: Tsai LC, Beavo JA. The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. Curr Opin Pharmacol. 2011 Dec;11(6):670-5. doi: 10.1016/j.coph.2011.09.003. Epub 2011 Sep 29. Review. PubMed PMID: 21962440; PubMed Central PMCID: PMC4034742. 19: Newby AC, Assender JW, Evans MA, Lim K, Bennett MR, Evan GI. Transduction pathways for growth stimulatory and inhibitory actions of vasoactive agents. Exp Nephrol. 1994 Mar-Apr;2(2):94-100. Review. PubMed PMID: 7521776. 20: Halaban R, Tyrrell L, Longley J, Yarden Y, Rubin J. Pigmentation and proliferation of human melanocytes and the effects of melanocyte-stimulating hormone and ultraviolet B light. Ann N Y Acad Sci. 1993 May 31;680:290-301. Review. PubMed PMID: 7685575.